Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178

Rhea-AI Filing Summary

Gossamer Bio director Skye Drynan received a new stock option grant as part of board compensation. The award covers 115,000 options to buy Gossamer Bio common stock at an exercise price of $0.178 per share, expiring on June 3, 2036.

The option was granted under the company’s Non-Employee Director Compensation Program and represents 115,000 underlying shares following this transaction. All option shares vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, assuming continued board service through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Drynan Skye

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	115,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 115,000 shares (Direct, null)

Footnotes (1)

1. Award made pursuant to Non-Employee Director Compensation Program. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Option grant size: 115,000 options Exercise price: $0.178 per share Underlying shares: 115,000 shares +2 more

5 metrics

Option grant size 115,000 options Stock option award to director Skye Drynan

Exercise price $0.178 per share Conversion or exercise price of options

Underlying shares 115,000 shares Common stock underlying the option grant

Post-grant option holdings 115,000 options Total options reported following this transaction

Option expiration date June 3, 2036 Expiration of the stock option award

Key Terms

Non-Employee Director Compensation Program, stock option, vested and exercisable, grant date

4 terms

Non-Employee Director Compensation Program financial

"Award made pursuant to Non-Employee Director Compensation Program."

stock option financial

"The entire number of shares subject to this option becomes fully vested and exercisable..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vested and exercisable financial

"The entire number of shares subject to this option becomes fully vested and exercisable..."

grant date financial

"the first anniversary of the grant date or (b) the next occurring annual meeting..."

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drynan Skye

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.178	06/04/2026		A		115,000(1)		(2)	06/03/2036	Common Stock	115,000	$0	115,000	D

Explanation of Responses:

1. Award made pursuant to Non-Employee Director Compensation Program.

2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Christian Waage, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Gossamer Bio (GOSS) director Skye Drynan receive in this Form 4 filing?

Skye Drynan received a stock option grant for 115,000 shares of Gossamer Bio common stock. The award is part of the Non-Employee Director Compensation Program and provides the right to buy shares at a fixed exercise price of $0.178 per share.

What is the exercise price and term of Skye Drynan’s GOSS stock options?

The stock options have an exercise price of $0.178 per share and expire on June 3, 2036. This long-dated term gives the director a multi-year window to decide whether to exercise the options, subject to vesting conditions being met.

When do Skye Drynan’s Gossamer Bio stock options vest?

All 115,000 stock options vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on Skye Drynan continuing to serve on Gossamer Bio’s board through the applicable vesting date.

Is Skye Drynan’s GOSS stock option grant an open-market purchase?

No. The transaction is a compensation-related stock option grant, not an open-market share purchase. It was awarded under Gossamer Bio’s Non-Employee Director Compensation Program, with an exercise price of $0.178 and vesting tied to continued board service.

How many Gossamer Bio option shares does Skye Drynan hold after this grant?

Following this grant, the Form 4 reports 115,000 stock option shares for Skye Drynan from this award. These options are linked to 115,000 underlying shares of Gossamer Bio common stock, subject to the described vesting schedule and the stated expiration date.